RxDoctor Payments Data

Tung Tran, MD

Gastroenterology · Denison, TXNPI 1396958484

Payments from drug & device makers

$170,786in general payments, 2019–2025

Across 506 payments — averaging $337.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$164K
  • Ironwood Pharmaceuticals, Inc$3K
  • Boston Scientific$654
  • Takeda Pharmaceuticals U.S.A., Inc.$571
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$344
  • Ardelyx, Inc.$306
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$2750%
  • Speaking & faculty fees$158,61393%
  • Travel & lodging$3,8782%
  • Food & beverage$7,9865%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,786 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$432,879
Medicare patients
966
Services billed
3,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$131,186
LinzessLinaclotide117$113,738
RinvoqUpadacitinib11$107,125
XifaxanRifaximin34$91,593
Humira(Cf)Adalimumab13$84,705
CreonLipase/Protease/Amylase24$82,583
Entyvio PenVedolizumab12$77,286
Dexlansoprazole DrDexlansoprazole66$23,154
Mesalamine DrMesalamine23$9,535
Pantoprazole Sodium743$8,947
Budesonide DrBudesonide53$8,840
MovantikNaloxegol Oxalate12$8,303
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag64$7,769
Mesalamine ErMesalamine15$5,720
Sucralfate149$5,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Rinvoq, Humira(Cf), Creon$163,855$388,151165 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$344$93,44047 claims
Braintree Laboratories, Inc.Suflave$109$7,76964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Denison

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →